ImpediMed Limited
IPDQF
$0.0445
$0.004812.09%
| Weiss Ratings | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 122.50% | |||
| 30-Day Total Return | 10.42% | |||
| 60-Day Total Return | 5.70% | |||
| 90-Day Total Return | -27.99% | |||
| Year to Date Total Return | 37.77% | |||
| 1-Year Total Return | -- | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -32.06% | |||
| 52-Week Low % Change | 122.50% | |||
| Price | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.07 | |||
| 52-Week Low Price | $0.02 | |||
| 52-Week Low Price (Date) | Jan 08, 2025 | |||
| 52-Week High Price (Date) | Oct 03, 2024 | |||
| Valuation | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 53.49M | |||
| Enterprise Value | 43.02M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | 0.00 | |||
| Earnings Per Share Growth | -11.11% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 4.49 | |||
| Enterprise Value/Revenue (TTM) | 5.65 | |||
| Price | $0.04 | |||
| Enterprise Value/EBITDA (TTM) | -3.25 | |||
| Enterprise Value/EBIT | -2.87 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 2.02T | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 760 585 2100 | |||
| Address | 5900 Pasteur Ct. Carlsbad, CA 92008 | |||
| Website | www.impedimed.com | |||
| Country | United States | |||
| Year Founded | 1999 | |||
| Profitability | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -196.65% | |||
| Profit Margin | -183.82% | |||
| Management Effectiveness | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -29.16% | |||
| Return on Equity | -- | |||
| Income Statement | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 7.67M | |||
| Total Revenue (TTM) | 7.61M | |||
| Revenue Per Share | $0.00 | |||
| Gross Profit (TTM) | 6.69M | |||
| EBITDA (TTM) | -13.23M | |||
| EBIT (TTM) | -14.97M | |||
| Net Income (TTM) | -14.00M | |||
| Net Income Avl. to Common (TTM) | -14.00M | |||
| Total Revenue Growth (Q YOY) | 25.57% | |||
| Earnings Growth (Q YOY) | -14.68% | |||
| EPS Diluted (TTM) | 0.00 | |||
| EPS Diluted Growth (Q YOY) | -- | |||
| Balance Sheet | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 10.95M | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 14.35M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 20.00M | |||
| Current Ratio (Q) | 4.571 | |||
| Book Value Per Share (Q) | $0.01 | |||
| Total Assets (Q) | 24.25M | |||
| Total Current Liabilities (Q) | 3.14M | |||
| Total Debt (Q) | 647.30K | |||
| Total Liabilities (Q) | 4.25M | |||
| Total Common Equity (Q) | 20.00M | |||
| Cash Flow | IPDQF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -1.33M | |||
| Cash from Financing (TTM) | -304.70K | |||
| Net Change in Cash (TTM) | -12.66M | |||
| Levered Free Cash Flow (TTM) | -9.15M | |||
| Cash from Operations (TTM) | -12.06M | |||
